Abstract
The Wiskott-Aldrich Syndrome (WAS) is a monogenic X-linked primary immunodeficiency characterised also by thrombocytopenia, eczema, and a high susceptibility to develop tumours and autoimmunity. WAS patients have a severely reduced life expectancy, unless they undergo a successful HLA-matched haematopoietic stem cell (HSC) transplantation. However, several WAS patients lack a compatible donor and complications, such as autoimmunity, can arise in a significant fraction of HSC transplanted patients. Administration of WAS gene-corrected autologous HSC represents an alternative therapeutic approach, potentially applicable to all WAS patients. To this aim, several gene therapy approaches for WAS using initially γ-retroviral vectors (RVs) and subsequently HIV-based lentiviral vectors (LVs) have been developed. In the present review, we will first describe the results of the preclinical studies conducted in the murine model of WAS and then discuss the outcome of different phase I/II clinical trials using RV or LV- transduced HSC. Both gene therapy approaches led to restored WASP expression, correction of functional defects and clinical improvement. While RV-mediated gene therapy was associated with a high occurrence of leukaemia, results obtained in the first patients treated with LV-based HSC gene therapy indicate a safer risk-benefit profile.
Keywords: Gene therapy, lentiviral vector, primary immunodeficiency, Wiskott-Aldrich syndrome.
Current Gene Therapy
Title:Gene Therapy for Wiskott-Aldrich Syndrome
Volume: 14 Issue: 6
Author(s): Marita Bosticardo, Francesca Ferrua, Marina Cavazzana and Alessandro Aiuti
Affiliation:
Keywords: Gene therapy, lentiviral vector, primary immunodeficiency, Wiskott-Aldrich syndrome.
Abstract: The Wiskott-Aldrich Syndrome (WAS) is a monogenic X-linked primary immunodeficiency characterised also by thrombocytopenia, eczema, and a high susceptibility to develop tumours and autoimmunity. WAS patients have a severely reduced life expectancy, unless they undergo a successful HLA-matched haematopoietic stem cell (HSC) transplantation. However, several WAS patients lack a compatible donor and complications, such as autoimmunity, can arise in a significant fraction of HSC transplanted patients. Administration of WAS gene-corrected autologous HSC represents an alternative therapeutic approach, potentially applicable to all WAS patients. To this aim, several gene therapy approaches for WAS using initially γ-retroviral vectors (RVs) and subsequently HIV-based lentiviral vectors (LVs) have been developed. In the present review, we will first describe the results of the preclinical studies conducted in the murine model of WAS and then discuss the outcome of different phase I/II clinical trials using RV or LV- transduced HSC. Both gene therapy approaches led to restored WASP expression, correction of functional defects and clinical improvement. While RV-mediated gene therapy was associated with a high occurrence of leukaemia, results obtained in the first patients treated with LV-based HSC gene therapy indicate a safer risk-benefit profile.
Export Options
About this article
Cite this article as:
Bosticardo Marita, Ferrua Francesca, Cavazzana Marina and Aiuti Alessandro, Gene Therapy for Wiskott-Aldrich Syndrome, Current Gene Therapy 2014; 14 (6) . https://dx.doi.org/10.2174/1566523214666140918103731
DOI https://dx.doi.org/10.2174/1566523214666140918103731 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo
Current Drug Metabolism Origins and Consequences of AID Expression in Lymphoid Neoplasms
Current Immunology Reviews (Discontinued) High-Dose Linoleic Acid Activated JAK2-STAT3 Signaling Pathway Involved in Cytokine Production and Lipogenesis in Pancreatic Exocrine Cells
Current Molecular Medicine Chemoresistance in High-Grade Gliomas: Relevance of Adenosine Signalling in Stem-Like Cells of Glioblastoma Multiforme
Current Drug Targets MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Gene Therapy for Haemophagocytic Lymphohistiocytosis
Current Gene Therapy Multiple Metamorphoses of CD38 from Prognostic Marker to Disease Modifier to Therapeutic Target in Chronic Lymphocytic Leukemia
Current Topics in Medicinal Chemistry Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Anticancer Actions of Omega-3 Fatty Acids - Current State and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry The Role of AMPK/mTOR Modulators in the Therapy of Acute Myeloid Leukemia
Current Medicinal Chemistry The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology
Current Medicinal Chemistry The Role of Antihistamine Drugs in Allergic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Coordinated Expression of Pax-5 and FAK1 in Metastasis
Anti-Cancer Agents in Medicinal Chemistry Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design The Design of Drug Candidate Molecules as Selective Inhibitors of Therapeutically Relevant Protein Kinases
Current Medicinal Chemistry The Prognosis and Treatment of Adult Acute Leukemia with 11q23/MLL According to the Fusion Partner
Current Cancer Therapy Reviews Metal-N-Heterocyclic Carbene Complexes as Anti-Tumor Agents
Current Medicinal Chemistry The Metabolomic Strategy in Tuberculosis Therapy
Combinatorial Chemistry & High Throughput Screening Apoptosis and Autophagy Induction As Mechanism of Cancer Prevention by Naturally Occurring Dietary Agents
Current Drug Targets Synthesis, Characterization by Means of IR, 1H, 13C - NMR and Biological Investigations on New Diorganotin Carboxylic Acid Derivatives
Letters in Drug Design & Discovery